Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available on the company’s Investor Relations website until at least September 1, 2026.
Waters is a global life sciences and diagnostics company focused on analytical technologies, informatics, and services for regulated, high-volume testing environments, supporting medicine development, food and water safety, and disease detection.
Waters (NYSE:WAT) and IMU Biosciences announced a strategic partnership to advance IMU’s AI-powered High Definition (HD) Immunology platform for immune mapping in cancer and other diseases.
The collaboration combines Waters Biosciences’ flow cytometry and single-cell technologies with IMU’s AI analytics to enable large-scale, real-time immune profiling and biomarker discovery, supported by data presented at CYTO 2026.
Waters (NYSE: WAT) launched the Waters TA Instruments Coin Cell Differential Scanning Calorimeter (DSC) to advance battery safety testing. The system integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway and battery failure.
Its whole-cell capsule design eliminates coin cell teardown, reducing sample preparation time by more than 90% while preserving sample integrity. With an industry-leading –80 °C to 600 °C temperature range and compatibility with MS, FTIR, and GC-MS, the Coin Cell DSC targets faster, multidimensional battery research. Orders are open, with shipments expected from August 2026.
Waters (NYSE:WAT) launched BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ reversed-phase columns to improve characterization of GLP-1 peptides, insulin, and lipid nanoparticles (LNPs). The platform delivers up to 3x faster GLP-1 analysis and 2x faster LNP component analysis with increased resolving power and sensitivity.
According to Waters, the new columns offer up to 2x higher resolution, QC batch-tested GLP‑1 and LNP methods, improved impurity detection, and compatibility across U(H)PLC and HPLC systems. Global availability begins June 9, 2026, starting with the 1.6 µm Phenyl-Hexyl+ phase.
Waters (NYSE: WAT) announced FDA 510(k) clearance for the BD BACTEC FXI Culture System, enabling U.S. commercialization for bloodstream infection and sepsis diagnostics. Clinical data showed a ~3-hour (~15%) faster mean time to detection versus the prior BD BACTEC FX system.
The fully automated platform offers automated gravimetric vial volume measurement, up to 60-vial automated loading (50% more than the leading competitor), and 480- or 960-vial configurations. The system is also available in Europe and Japan following CE marking and PMDA licensing.
Waters (NYSE: WAT) unveiled the Xevo MRT P10 Mass Spectrometer, a benchtop high-resolution QToF system for high-throughput multiomics, bioanalysis, and biopharma labs. It delivers up to 20x higher MS/MS sensitivity and 2x faster acquisition than its predecessor, with advanced acquisition modes.
According to Waters, the system supports targeted and untargeted LC‑MS/MS, identifies up to 40% more lipids than a leading alternative, and, with the DESI XS source, enables MS imaging up to 200 Hz with six-fold higher throughput. Global availability is expected in summer 2026.
Waters (NYSE: WAT) launched the Cyclic IMS P20 Mass Spectrometer, a high-resolution structural and spatial omics platform unveiled at ASMS 2026. It combines multipass Cyclic Ion Mobility Spectrometry with advanced fragmentation, probing, and imaging to enhance early disease signal detection and biotherapeutic development.
The system delivers >10x higher MS/MS sensitivity than its predecessor, a >50% extended upper mass range to >100 kDa, and integrates MALDI XS and DESI XS imaging. Global availability is expected from September 2026.
Waters (NYSE:WAT) announced that President and CEO Udit Batra, Ph.D., will join a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 AM ET.
A live webcast and 90-day replay will be available on Waters' investor relations site.
Waters Corporation (NYSE: WAT) reported Q1 2026 revenue of $1.267 billion, above guidance by $56 million, driven by $747 million organic revenue (13% as reported, 11% cc) and $520 million from the acquired Biosciences and Diagnostic Solutions businesses. Adjusted EPS was $2.70 (+20% YoY); GAAP EPS was a loss of $0.87 reflecting acquisition accounting. The company raised full‑year organic growth guidance to 6.5–8.0% and adjusted EPS guidance to $14.40–$14.60, and now expects acquired business revenue of $3.035 billion in 2026.
Waters Corporation (NYSE:WAT) will report Q1 2026 results and host a conference call on May 5, 2026 at 8:30 a.m. ET.
A live webcast will be available on Waters Investor Relations, and a replay will remain available through at least June 2, 2026.